Welcome to our dedicated page for Precision Biosciences news (Ticker: DTIL), a resource for investors and traders seeking the latest updates and insights on Precision Biosciences stock.
Precision Biosciences, Inc. (DTIL) is a biotechnology innovator advancing the ARCUS genome editing platform for therapeutic and agricultural solutions. This page serves as the definitive source for verified company news, providing investors and industry professionals with timely updates on scientific milestones and corporate developments.
Access consolidated information on regulatory filings, research breakthroughs, and strategic partnerships directly impacting DTIL's position in the genome editing sector. Our curated feed includes earnings announcements, clinical trial updates, and technology licensing agreements, enabling informed analysis of the company's progress.
Key focus areas include ARCUS platform advancements in gene therapy programs, allogeneic CAR-T developments, and agricultural biotechnology applications. Users can track patent approvals, peer-reviewed study publications, and executive leadership updates through our chronologically organized news archive.
Bookmark this page for streamlined access to Precision Biosciences' official communications and third-party analysis. Check regularly for updates on how DTIL's precision gene editing technology continues to shape the future of genomic medicine and sustainable agriculture.
On May 6, 2022, Precision BioSciences (NASDAQ: DTIL) announced the grant of inducement awards under its 2021 Employment Inducement Incentive Award Plan. These awards consist of stock options totaling 401,905 shares, granted to four new employees who started on March 14, 2022. The options have an exercise price of $1.94, equal to the fair market value on the grant date, and a 10-year term with a vesting schedule. Precision BioSciences focuses on developing ARCUS-based gene editing therapies aimed at treating genetic and infectious diseases.
Precision BioSciences (Nasdaq: DTIL) reported a significant revenue decline to $3.3 million in Q1 2022 from $16.3 million in Q1 2021, primarily due to decreased income from its agreements with Servier and Lilly. R&D expenses decreased to $20 million from $25.6 million, while general and administrative costs rose to $10.7 million. The company posted a net loss of $28.2 million, compared to a loss of $18.7 million a year earlier. Key updates include anticipated progress in their CAR T programs and in vivo gene editing initiatives, with updates planned for June 2022.
Precision BioSciences (Nasdaq: DTIL) announced that four abstracts, including a collaborative research project, were accepted for presentation at the American Society of Gene & Cell Therapy (ASGCT) annual meeting from May 16-19, 2022, in Washington, D.C..
The presentations will focus on advancements in ARCUS® gene editing therapies. Highlights include oral presentations on targeting Hepatitis B and gene targeting in macaques, as well as poster presentations on optimizing ARCUS nucleases for treating specific genetic diseases.
Precision BioSciences, Inc. (Nasdaq: DTIL) has announced its participation in the H.C. Wainwright Global Investment Conference on
Precision BioSciences (DTIL) announced significant advancements in gene editing and CAR T therapies. For 2021, revenues surged to $115.5 million, up from $24.3 million in 2020, attributed to strategic partnerships with Servier, Lilly, and iECURE. R&D expenses rose to $115.2 million from $98.1 million, reflecting investments in its innovative ARCUS platform. The net loss narrowed to $30.6 million, or $(0.52) per share. Going forward, the company aims to advance three in vivo programs to IND in three years and updates on allogenic CAR T clinical studies are anticipated in mid-2022.
Precision BioSciences, Inc. (Nasdaq: DTIL) will publish its financial results for Q4 and fiscal year 2021 on March 15, 2022, alongside a business update. The company focuses on developing ARCUS®-based ex vivo CAR T and in vivo gene editing therapies aimed at treating genetic and infectious diseases lacking adequate treatments. With its proprietary ARCUS platform, Precision BioSciences aims for therapeutic safety and control.
Atomwise, a leader in AI-driven small molecule drug discovery, has appointed David Thomson, Ph.D., as Chief Scientific Officer, alongside Jonathan Barr as Chief Financial Officer and Jeffrey Cerio, Pharm.D., J.D., as General Counsel. Dr. Thomson will spearhead the company's drug development strategy, focusing on enhancing their small molecule pipeline. His extensive experience includes leadership roles at Precision BioSciences and Shire. Barr brings expertise from Bridge Bio, where he managed significant capital raises. Cerio has a strong legal background from Moderna. The team aims to advance Atomwise's innovative drug discovery capabilities.
Precision BioSciences (Nasdaq: DTIL) announced that CEO Michael Amoroso will provide a corporate update at the annual J.P. Morgan Health Care Conference on January 12, 2022, from 2:15 - 2:55 PM ET. He will be joined by co-founder Derek Jantz, CFO Alex Kelly, and CMO Alan List for a Q&A session. The presentation will be available via a live webcast on the company's website, along with archived materials. Precision BioSciences is focused on developing innovative CAR T therapies using its proprietary ARCUS genome editing platform.
Precision BioSciences has announced an agreement with a syndicate led by ACCELR8 to separate its wholly owned Elo Life Systems subsidiary into an independent entity. This strategic move allows Elo to focus on food and agriculture, while Precision BioSciences can concentrate on human therapeutics utilizing its ARCUS® genome editing platform. Precision maintains an equity stake in Elo, and all employees transitioned to the new company. The separation aims to enhance operational success for both entities.
Precision BioSciences (DTIL) has reported promising updates on its allogeneic CAR T cell therapies, PBCAR0191 and PBCAR19B. In a Phase 1/2a study, PBCAR0191 showed a 73% overall response rate and a 59% complete response rate among heavily pre-treated patients. Notably, 100% of patients who had prior autologous CAR T therapy responded to PBCAR0191. The company is also progressing with PBCAR19B, which aims to be a best-in-class CD19 therapy. As of November 30, 2021, Precision holds approximately $152 million in cash, supporting operations into 2023.
